AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22446996 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 3761
Study 20155996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum 900 mg/day
Number of subjects: 36
Study 20155996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20155996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum
Number of subjects: 36
Study 18296545 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective coil occlusion
Number of subjects: 16
Study 18296545 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ICA occlusion
Number of subjects: 16
Study 15979426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary aqueous oxygen
Number of subjects: 50
Study 15979426 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 14764997 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome participants
Number of subjects: 0
Study 14764997 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy control participants
Number of subjects: 0
Study 12973385 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate (Seroquel®)
Number of subjects: 0
Study 9031875 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP (diphtheria and tetanus toxoid acellular pertussis vaccine)
Number of subjects: 286
Study 9031875 — intervention group
Group type: COMPARATOR
Intervention: DTwP (diphtheria and tetanus toxoid whole-cell pertussis vaccine)
Number of subjects: 286
Study 9031875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTaP and DTwP
Number of subjects: 286
Study 1653966 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial complementary programme
Number of subjects: 65
Study 6427817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diazepam
Number of subjects: 120
Study 6427817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diazepam
Number of subjects: 120
Study 6427817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 120
Study 6427817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30776134 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 (0.1, 0.3, 1, 3, and 10 mg/kg IV; 1 mg/kg SC)
Number of subjects: 54
Study 30776134 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 (IV administration)
Number of subjects: 54
Study 30776134 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 (1 mg/kg SC)
Number of subjects: 54
Study 30776134 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 (active treatment)
Number of subjects: 54
Study 29149379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic corticosteroids (IT)
Number of subjects: 112
Study 29149379 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 112
Study 29149379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IT plus systemic)
Number of subjects: 112
Study 29149379 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 112
Study 27386647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanshinone IIA (T II A) at 80 mg/day for 3 successive days before oxaliplatin chemotherapy
Number of subjects: 36
Study 27386647 — intervention group
Group type: COMPARATOR
Intervention: Control group (oxaliplatin alone)
Number of subjects: 36
Study 27386647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanshinone IIA (T II A)
Number of subjects: 36
Study 24471975 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-category response scale mail survey
Number of subjects: 6500
Study 24471975 — intervention group
Group type: COMPARATOR
Intervention: 6-category response scale mail survey
Number of subjects: 6500
Study 24471975 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-category response scale telephone survey
Number of subjects: 6500
Study 24471975 — intervention group
Group type: COMPARATOR
Intervention: 6-category response scale telephone survey
Number of subjects: 6500
Study 24471975 — intervention group
Group type: COMPARATOR
Intervention: 12-page mail survey
Number of subjects: 6500
Study 24471975 — intervention group
Group type: EXPERIMENTAL
Intervention: four-page mail survey
Number of subjects: 6500
Study 22298793 — intervention group
Group type: COMPARATOR
Intervention: SLE with Therapy (480 patients)
Number of subjects: 555
Study 22298793 — intervention group
Group type: COMPARATOR
Intervention: SLE No Therapy (75 patients)
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) monotherapy (105 patients)
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PRED) ≥20 mg (76 patients)
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressor (IS) (95 patients)
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: PRED ≥20 mg + IS
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: PRED ≥20 mg + CQ
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: IS + CQ
Number of subjects: 555
Study 22298793 — intervention group
Group type: EXPERIMENTAL
Intervention: PRED ≥20 mg + IS + CQ
Number of subjects: 555
Study 19825910 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study 19825910 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 22
Study 17587564 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin/5‐FU/FA
Number of subjects: 0
Study 17587564 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/FA alone
Number of subjects: 0
Study 18024208 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (supervised training for 10 weeks)
Number of subjects: 34
Study 18024208 — intervention group
Group type: COMPARATOR
Intervention: Routine exercises (exercise group for 10 weeks)
Number of subjects: 34
Study 15005875 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg kg(‐1)) infused over 3 min
Number of subjects: 12
Study 15005875 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg, four times a day)
Number of subjects: 12
Study 15005875 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg kg(‐1))
Number of subjects: 12
Study 15005875 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron with cimetidine
Number of subjects: 12
Study 11223726 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory warm-up (RWU) prior to measurement
Number of subjects: 14
Study 11223726 — intervention group
Group type: COMPARATOR
Intervention: Control (no warm-up)
Number of subjects: 14
Study 9425399 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 micrograms daily for 1 month)
Number of subjects: 48
Study 9425399 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin receptor scintigraphy
Number of subjects: 48
Study 8214737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg/kg) followed by placebo (NaCl 0.9%)
Number of subjects: 8
Study 8214737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg/kg) followed by midazolam (0.1 mg/kg)
Number of subjects: 8
Study 8214737 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by midazolam (0.1 mg/kg)
Number of subjects: 8
Study 3479443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral approach
Number of subjects: 40
Study 3479443 — intervention group
Group type: COMPARATOR
Intervention: Extraoral approach
Number of subjects: 40
Study 3479443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 40
Study 30821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement (100 mg Lactobacillus coagulans and fructo‐oligosaccharides, 2 tablets per day for 8 weeks)
Number of subjects: 50
Study 30821897 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement
Number of subjects: 50
Study 30821897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28986234 — intervention group
Group type: EXPERIMENTAL
Intervention: BFRE training (4 weeks)
Number of subjects: 9
Study 28986234 — intervention group
Group type: COMPARATOR
Intervention: High intensity training (O-HI, 4 weeks at 75% MVC)
Number of subjects: 9
Study 28986234 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (Y-BFRE, 4 weeks)
Number of subjects: 9
Study 24621965 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored telephone counseling
Number of subjects: 193
Study 24621965 — intervention group
Group type: COMPARATOR
Intervention: National Cancer Institute brochure
Number of subjects: 193
Study 24620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy (40-60 minutes a day, 3-4 days a week)
Number of subjects: 32
Study 24620666 — intervention group
Group type: COMPARATOR
Intervention: Conventional symptomatic treatment
Number of subjects: 32
Study 24620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy
Number of subjects: 32
Study 21697896 — intervention group
Group type: EXPERIMENTAL
Intervention: Short leukocyte telomere length
Number of subjects: 1271
Study 21697896 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of short telomeres (shorter than 5 kb)
Number of subjects: 1271
Study 21697896 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of short telomeres
Number of subjects: 1271
Study 19782875 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRA score 0 to 1 group
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRA score 7 or higher group
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRA sum score
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-group CAPRA score
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-group CAPRA score
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRA score 0 to 1
Number of subjects: 1296
Study 17868719 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPRA score 7 to 10
Number of subjects: 1296
Study 15731536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (Group II)
Number of subjects: 200
Study 15731536 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isosorbide dinitrate (Group I)
Number of subjects: 200
Study 12000479 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured parental training program (inter‐disciplinary, educational program covering medical, nutritional, and psychological issues in six group sessions of 2 hours each)
Number of subjects: 204
Study 12000479 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured parental training program
Number of subjects: 204
Study 12000479 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (who could participate in the training program 1 year later)
Number of subjects: 204
Study 9578120 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery ablation of the adenoid
Number of subjects: 24
Study 9578120 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 24
Study 9578120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 7659475 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccines
Number of subjects: 2342
Study 7659475 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell vaccine (WCL)
Number of subjects: 2342
Study 2485347 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula of parenteral nutrition
Number of subjects: 14
Study 2485347 — intervention group
Group type: COMPARATOR
Intervention: Standard formula of parenteral nutrition
Number of subjects: 14
Study 1173763 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparation SA (Eryfer)
Number of subjects: 0
Study 1173763 — intervention group
Group type: COMPARATOR
Intervention: Iron preparation SC (effervescent tablet)
Number of subjects: 0
Study 1173763 — intervention group
Group type: COMPARATOR
Intervention: Iron preparation SD (sustained release)
Number of subjects: 0
Study 1173763 — intervention group
Group type: COMPARATOR
Intervention: Iron preparation SE (enteric-coated pellets)
Number of subjects: 0
Study 30693966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute breathing (mindfulness) exercise
Number of subjects: 18
Study 30693966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness exercise)
Number of subjects: 18
Study 27984823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 25 mg 1 qd for maximal 7 days
Number of subjects: 50
Study 27984823 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 qd for maximal 7 days
Number of subjects: 50
Study 25456878 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE II (ESII)
Number of subjects: 304
Study 25456878 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic EuroSCORE (LES)
Number of subjects: 304
Study 25456878 — intervention group
Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons Predicted Risk of Mortality (STS‐PROM)
Number of subjects: 304
Study 23843147 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 1864
Study 23843147 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 1864
Study 23843147 — intervention group
Group type: COMPARATOR
Intervention: Reference group (apnea-hypopnea index <15/hour)
Number of subjects: 1864
Study 21270386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate diet (75 ± 1% of calorie intake from fat)
Number of subjects: 16
Study 21270386 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard diet (23 ± 1% of calorie intake from fat)
Number of subjects: 16
Study 19255028 — intervention group
Group type: EXPERIMENTAL
Intervention: PURPLE education materials
Number of subjects: 2738
Study 16616167 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to Treatment Inventory (BTI) administered to substance abusers
Number of subjects: 312
Study 15629765 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 64
Study 15629765 — intervention group
Group type: EXPERIMENTAL
Intervention: Family ratings of motor functioning
Number of subjects: 64
Study 15629765 — intervention group
Group type: EXPERIMENTAL
Intervention: PET with [18F]FDG
Number of subjects: 64
Study 15629765 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor ratings
Number of subjects: 64
Study 15629765 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing and family ratings of motor functioning
Number of subjects: 64
Study 11890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone low dose (LD) - bolus 27 microg/kg; continuous 50 microg/kg/hr
Number of subjects: 24
Study 11890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone high dose (HD) - bolus 54.5 microg/kg; continuous 100 microg/kg/hr
Number of subjects: 24
Study 11890592 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 9399710 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-guided strategy
Number of subjects: 496
Study 9399710 — intervention group
Group type: EXPERIMENTAL
Intervention: AECG ischemia-guided strategy
Number of subjects: 496
Study 9399710 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategy
Number of subjects: 496
Study 9399710 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment strategies
Number of subjects: 496
Study 9399710 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization group strategy
Number of subjects: 496
Study 7699476 — intervention group
Group type: EXPERIMENTAL
Intervention: GCNS monitoring with daily patient visits
Number of subjects: 33
Study 7699476 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 3109663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg initially, followed by 4 mg every six hours)
Number of subjects: 17
Study 3109663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31876883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine mesh (experimental group)
Number of subjects: 132
Study 31876883 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh (control group)
Number of subjects: 132
Study 31724348 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinyang Ruyin acupuncture
Number of subjects: 180
Study 31724348 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 180
Study 31724348 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (medication group)
Number of subjects: 180
Study 28336185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding metallic stent as a bridge to surgery
Number of subjects: 82
Study 28336185 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 82
Study 26483858 — intervention group
Group type: EXPERIMENTAL
Intervention: DOPS (Direct Observation of Procedural Skills)
Number of subjects: 193
Study 26483858 — intervention group
Group type: COMPARATOR
Intervention: Tutor teaching (classical tutor system)
Number of subjects: 193
Study 26483858 — intervention group
Group type: EXPERIMENTAL
Intervention: DOPS
Number of subjects: 193
Study 23707115 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPAR peptide assay (0.05-0.40 ng/mL for controls, 1.0-8.5 ng/mL for concussions)
Number of subjects: 124
Study 23707115 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPAR peptide values in athletes with multiple concussions (2.0-12.0 ng/mL)
Number of subjects: 124
Study 23707115 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive tests (ImPACT)
Number of subjects: 124
Study 23707115 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 91)
Number of subjects: 124
Study 21406148 — intervention group
Group type: EXPERIMENTAL
Intervention: NUK pacifier (N; N=73)
Number of subjects: 129
Study 21406148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentistar pacifier (D; N=56)
Number of subjects: 129
Study 21406148 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; N=42)
Number of subjects: 129
Study 19595184 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hepatic carcinoma group
Number of subjects: 20
Study 19595184 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study 19595184 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B group
Number of subjects: 20
Study 19595184 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B cirrhosis group
Number of subjects: 20
Study 16491871 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 120
Study 16491871 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 120
Study 16491871 — intervention group
Group type: EXPERIMENTAL
Intervention: HealonV
Number of subjects: 120
Study 15208586 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone, 500 microg twice daily for 14 days
Number of subjects: 88
Study 15208586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 10937294 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy tasks
Number of subjects: 40
Study 10937294 — intervention group
Group type: COMPARATOR
Intervention: Phonological decoding abilities
Number of subjects: 40
Study 9636522 — intervention group
Group type: COMPARATOR
Intervention: MMF 1 g
Number of subjects: 0
Study 9636522 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 0
Study 9636522 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g (mean dose adjusted to 1.5 g by 6 months)
Number of subjects: 0
Study 9636522 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 0
Study 8160943 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms.kg-1 at induction and another 4 micrograms.kg-1 before skin incision (group A)
Number of subjects: 80
Study 8160943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (same dose) plus clonidine 4 micrograms.kg-1 in 20 min + 2 micrograms.kg-1.h-1 (group B)
Number of subjects: 80
Study 8160943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group C)
Number of subjects: 80
Study 8160943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group D)
Number of subjects: 80
Study 2829492 — intervention group
Group type: EXPERIMENTAL
Intervention: Antileukaemic protocol
Number of subjects: 0
Study 31586244 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 261
Study 31586244 — intervention group
Group type: COMPARATOR
Intervention: laTME
Number of subjects: 261
Study 31077432 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided dosing of paclitaxel
Number of subjects: 319
Study 31077432 — intervention group
Group type: COMPARATOR
Intervention: BSA-based dosing of paclitaxel
Number of subjects: 319
Study 28259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose screening chest CT
Number of subjects: 17309
Study 25232856 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 669
Study 25232856 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 669
Study 25232856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 669
Study 25232856 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling for minority women
Number of subjects: 669
Study 23850386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin applied on the skin of the thigh
Number of subjects: 18
Study 23850386 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied on the contralateral thigh
Number of subjects: 18
Study 21346159 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose remifentanil (0.2 μg · kg(‐1) · min(‐1))
Number of subjects: 60